Sulfonylureas

Journal of the Pakistan Medical Association

Volumn 65, Issue 1, 2015, Pages 101-104

  Kalra, Sanjay ^a   Gupta, Yashdeep ^b  

^a India   (India)

^b GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Diabetes; Glibenclamide; Gliclazide; Glimepiride; Glipizide; Oral antidiabetic drugs

Indexed keywords

ANTIPORTER; EPAC 2 PROTEIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; RAP1 PROTEIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ARTICLE; BLOOD GLUCOSE MONITORING; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; END STAGE RENAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; META ANALYSIS (TOPIC); ORAL CLEARANCE; PANCREAS ISLET BETA CELL; PHARMACOGENOMICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); VASCULAR SMOOTH MUSCLE CELL; DIABETES MELLITUS, TYPE 2;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; SULFONYLUREA COMPOUNDS;

EID: 84925587932     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 2012;125:302.e1-7.
2. Eldor R, Raz I. Diabetes therapy--focus on Asia: second-line therapy debate: insulin/secretagogues. Diabetes Metab Res Rev 2012;28 Suppl 2:85-9.
3. Seino S. Cell signalling in insulin secretion: the molecular targets of ATP, cAMP and sulfonylurea. Diabetologia 2012;55:2096-108.
4. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013;56:973-84.
5. Forst T, Hanefeld M, Jacob S, Moeser G, Schwenk G, Pfützner A, et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res 2013;10:302-14.
6. Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2013;4:CD009008.
7. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 2012;17:813-22.
8. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 2013;62:922-34.
9. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 2011;12:1161-91.
10. Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013;9:529-50.
11. Ahmadieh H, Azar ST. Liver disease and diabetes: association, pathophysiology, and management. Diabetes Res Clin Pract 2014;104:53-62.
12. Rattarasam C, Thamprasit A, Leelawattana R, Soonthompun S, Setasuban W. The role of diminished beta cell reserve and insulin resistance in secondary sulfonylurea failure of type 2 diabetes mellitus. J Med Assoc Thailand 2001;84:1754-62.
13. Ragia G, Tavridou A, Elens L, Van Schaik RH, Manolopoulos VG. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. Exp Clin Endocrinol Diabetes 2014;122:60-3.
14. Phani N, Rai P, Adhikari P, Nagri S, D'Souza S, Gopinath M, Satyamoorthy K. Impact of KCNJ11, TCF7L2, SLC30A8, IGF2BP2, PPARG, SLC47A1, STK11, HHEX, KCNQ1, CDKAL1, FTO, CYP2C9, ADIPOQ, CAPN10 gene polymorphisms on risk of type 2 diabetes and therapeutic response to sulfonylurea and metformin therapy. Molecular Cytogenetics 2014; 7(Suppl 1), P100.
15. Kahn SE, Haffner SM, Heise MA, Hermann WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-43.
16. Rustenbeck I, Baltrusch S, Tiedge M. Do insulinotropic glucoselowering drugs do more harm than good? The hypersecretion hypothesis revisited. Diabetologia 2010;53:2105-11.
17. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obesity Metab 2013;5:938-53.